<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/AABC0E98-CD3E-4417-9B0A-536F2E1F1D91"><gtr:id>AABC0E98-CD3E-4417-9B0A-536F2E1F1D91</gtr:id><gtr:name>Royal College of Paediatrics and Child Health (RCPCH)</gtr:name></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/5E2B04DD-4A03-45ED-9892-61C5CCB8AC68"><gtr:id>5E2B04DD-4A03-45ED-9892-61C5CCB8AC68</gtr:id><gtr:name>Newcastle University</gtr:name><gtr:department>Unlisted</gtr:department><gtr:address><gtr:line1>1 Park Terrace</gtr:line1><gtr:line4>Newcastle Upon Tyne</gtr:line4><gtr:line5>Tyne and Wear</gtr:line5><gtr:postCode>NE1 7RU</gtr:postCode><gtr:region>North East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/5E2B04DD-4A03-45ED-9892-61C5CCB8AC68"><gtr:id>5E2B04DD-4A03-45ED-9892-61C5CCB8AC68</gtr:id><gtr:name>Newcastle University</gtr:name><gtr:address><gtr:line1>1 Park Terrace</gtr:line1><gtr:line4>Newcastle Upon Tyne</gtr:line4><gtr:line5>Tyne and Wear</gtr:line5><gtr:postCode>NE1 7RU</gtr:postCode><gtr:region>North East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role><gtr:role><gtr:name>FELLOW</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/AABC0E98-CD3E-4417-9B0A-536F2E1F1D91"><gtr:id>AABC0E98-CD3E-4417-9B0A-536F2E1F1D91</gtr:id><gtr:name>Royal College of Paediatrics and Child Health (RCPCH)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/B6B5BD4C-762D-47E9-9174-B30137F85B33"><gtr:id>B6B5BD4C-762D-47E9-9174-B30137F85B33</gtr:id><gtr:firstName>Robert</gtr:firstName><gtr:surname>McFarland</gtr:surname><gtr:roles><gtr:role><gtr:name>FELLOW</gtr:name></gtr:role><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G108%2F539"><gtr:id>8368E2E7-3A73-4C1E-9209-76D07142BC83</gtr:id><gtr:title>The role of homoplasmic mitochondrial tRNA mutations in disease</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Fellowship</gtr:grantCategory><gtr:grantReference>G108/539</gtr:grantReference><gtr:abstractText>Mitochondria are the ?powerhouses? of the cell converting energy locked in foodstuffs into a form that fuels the cellular processes essential for life. Uniquely, they contain multiple copies of their own maternally inherited DNA, distinct from nuclear DNA. Mitochondrial DNA (mtDNA) encodes information necessary to make proteins required for this energy conversion. Mutations (errors) occur frequently in mtDNA, but because there are lots of copies of mtDNA in each mitochondrion, illness (e.g. heart disease, diabetes and epilepsy), is often not evident until a large proportion of mtDNA is mutated. The proportion of mutated to wild type mtDNA (heteroplasmy) can vary from cell to cell and organ to organ and in some cases the mtDNA is entirely mutant (homoplasmic). Discriminating homoplasmic mutations which cause disease (pathogenic) from those that are benign, (polymorphisms), can be very difficult. My preliminary results indicate that pathogenic homoplasmic mutations are more common than previously anticipated and result in both organ-specific and multi-system diseases. Extraordinarily, within families inheriting these pathogenic homoplasmic mutations some individuals remain symptom free, suggesting that other factors are crucial for the development of disease. My aims are to establish the clinical importance of homoplasmic mutations by developing a technique for easy and rapid detection of pathogenicity and also, to investigate the factors which influence the development of disease in particular individuals but not others. Fulfilling these aims will further our understanding of mitochondrial-nuclear interactions and the processes that determine clinical outcome in mitochondrial diseases. Moreover it will then be possible to ascertain the true incidence of mitochondrial disease, provide accurate genetic counselling to affected families and to begin development of targeted treatment strategies.</gtr:abstractText><gtr:technicalSummary>Mitochondrial DNA disease is a relatively new, rapidly evolving and clinically important area of medicine. Within this field, I have been particularly interested in the clinical features, incidence and pathogenesis of homoplasmic mitochondrial tRNA (mt-tRNA) mutations. Despite the involvement of all mtDNA molecules, patients with homoplasmic mt-tRNA disease have remarkable clinical variability - some of the mutations are associated with tissue specific symptoms, yet others induce severe systemic disease. Perhaps even more remarkable is the observation that some patients with homoplasmic mitochondrial tRNA mutations are asymptomatic, whilst their offspring have died with severe systemic disease. Even detecting or recognising these mutations is a major problem due to the highly polymorphic nature of the mitochondrial genome. I have recently detected three such families in the Newcastle area, which raises important questions as to the underlying frequency of these mutations within the population. Thus, the clinical diversity, tissue selectivity and complex molecular biology of homoplasmic mt-tRNA mutations present major clinical, diagnostic and particularly aetiological challenges.
The aim of this proposal is to focus on these problems and I intend to:
1. Firmly establish the clinical importance of homoplasmic mt-tRNA mutations by developing both bioinformatic approaches and real-time PCR methods of identifying mutations with potential to cause human disease.
2. Address the aetiological basis of homoplasmic mt-tRNA disease by ascertaining the factors, mitochondrial, nuclear and tissue specific, that are ultimately responsible for the aetiology of disease in patients with these mutations. Specifically, I wish to identify any mtDNA suppressor mutations; to determine the cause of the differences in mt-tRNA levels and protein synthesis between immature and mature muscle; and to identify important modifying factors in asymptomatic patients.
In order complete these objectives I intend to collaborate with colleagues in various institutions specialising in particular aspects of this work. Specifically, this will include work on mitochondrial tRNA sequence variation, (Dr J Elson [MRC Bioinformatics Training Fellow, Newcastle] and Dr N Howell [Department of Human Biology and Genetics, University of Texas]), physiological modifying factors (Dr T Taivassalo [Exercise Physiologist, Dallas, Texas]) and investigation of factors involved in regulating mt-tRNA levels in mitochondria (Dr L Sweetlove [BBSRC Research Fellow, University of Oxford]).</gtr:technicalSummary><gtr:fund><gtr:end>2008-08-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2003-09-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>666577</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>Royal College of Paediatrics and Child Health (RCPCH)</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>PIND</gtr:description><gtr:id>19182DF5-C0B5-408B-9E71-667DFEE33812</gtr:id><gtr:impact>Verity CM, Winstone AM, Stellitano L, Krishnakumar D, Will R, McFarland R 'The clinical presentation of mitochondrial diseases in children with progressive intellectual and neurological deterioration: a national, prospective, population-based study'. Dev Med Child Neurol 2009 Sep 11 [Epub] 19747204</gtr:impact><gtr:outcomeId>A015582852D-1</gtr:outcomeId><gtr:piContribution>Review and identification of potential mitochondrial causes for PIND. Contributed to resulting research publication in 2009.</gtr:piContribution><gtr:sector>Multiple</gtr:sector><gtr:start>2008-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Mitochondrial Patient Information Forum</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>DD48EA4B-F32A-449B-997B-552076633242</gtr:id><gtr:impact>Platform presentation to audience of patients and their relatives

Increased numbers of patients with mitochondrial disease volunteering to participate in clinical research</gtr:impact><gtr:outcomeId>15A58CB28A2</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:year>2007,2008,2009,2010,2012</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>250000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>HEFCE Clinical Senior Lecturer Award</gtr:description><gtr:end>2013-07-02</gtr:end><gtr:fundingOrg>Higher Education Funding Council for England (HEFCE)</gtr:fundingOrg><gtr:id>6A9410DD-6B3F-4072-9D5C-A41200ACFDD5</gtr:id><gtr:outcomeId>A00FA55783F0</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2008-08-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>691000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC Cohorts Initiative</gtr:description><gtr:end>2012-02-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>FFCC50A9-5915-4C18-A2FF-B56F4FD62B0D</gtr:id><gtr:outcomeId>9DFC8944AB60</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2009-03-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>International Coordinating Committee for Standards of Care in Mitochondrial Medicine</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:id>426F653B-8B21-4019-B5E7-140C06B0AAAA</gtr:id><gtr:outcomeId>PUYRrUG7qky</gtr:outcomeId><gtr:type>Membership of a guidance committee</gtr:type></gtr:policyInfluenceOutput></gtr:policyInfluenceOutputs><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>BE5D017A-D587-4D0C-8874-B99DC0489308</gtr:id><gtr:title>A scale to monitor progression and treatment of mitochondrial disease in children.</gtr:title><gtr:parentPublicationTitle>Neuromuscular disorders : NMD</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/af38bba5d00fdbaaf876e9605f8bca32"><gtr:id>af38bba5d00fdbaaf876e9605f8bca32</gtr:id><gtr:otherNames>Phoenix C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0960-8966</gtr:issn><gtr:outcomeId>F4929CDE2FF</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4BD0C267-FEEF-4395-B7A0-097172C12366</gtr:id><gtr:title>The m.3291T&amp;gt;C mt-tRNA(Leu(UUR)) mutation is definitely pathogenic and causes multisystem mitochondrial disease.</gtr:title><gtr:parentPublicationTitle>Journal of the neurological sciences</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d934800bba4c6d737acf332a3f88b99e"><gtr:id>d934800bba4c6d737acf332a3f88b99e</gtr:id><gtr:otherNames>Yarham JW</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0022-510X</gtr:issn><gtr:outcomeId>pm_15296_26_23273904</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>85656106-0AE5-4E61-BBDB-10E8206D4EE9</gtr:id><gtr:title>Diabetes and deafness: is it sufficient to screen for the mitochondrial 3243A&amp;gt;G mutation alone?</gtr:title><gtr:parentPublicationTitle>Diabetes care</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0e87940e6460d8a108148a5e207bd528"><gtr:id>0e87940e6460d8a108148a5e207bd528</gtr:id><gtr:otherNames>Whittaker RG</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0149-5992</gtr:issn><gtr:outcomeId>39FBE89EFC6</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FE8C68F9-84BA-4766-84DF-26545F497377</gtr:id><gtr:title>Further pitfalls in the diagnosis of mtDNA mutations: homoplasmic mt-tRNA mutations.</gtr:title><gtr:parentPublicationTitle>Journal of medical genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/fe9015226fe85aa441230a01ec3c9484"><gtr:id>fe9015226fe85aa441230a01ec3c9484</gtr:id><gtr:otherNames>Tuppen HA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0022-2593</gtr:issn><gtr:outcomeId>5CA15C79A72</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>442B3FE6-C94B-4C23-9DD1-2C134806CF9A</gtr:id><gtr:title>Homoplasmy, heteroplasmy, and mitochondrial dystonia.</gtr:title><gtr:parentPublicationTitle>Neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/aceeebe176b2a13722db7069cd6fe796"><gtr:id>aceeebe176b2a13722db7069cd6fe796</gtr:id><gtr:otherNames>McFarland R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0028-3878</gtr:issn><gtr:outcomeId>8EEF9F9F474</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>62A099A8-5DFD-46E4-AF0A-CECD90F0CE2A</gtr:id><gtr:title>Mitochondrial disease--its impact, etiology, and pathology.</gtr:title><gtr:parentPublicationTitle>Current topics in developmental biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/aceeebe176b2a13722db7069cd6fe796"><gtr:id>aceeebe176b2a13722db7069cd6fe796</gtr:id><gtr:otherNames>McFarland R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0070-2153</gtr:issn><gtr:outcomeId>74DF64DF6E2</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>60F0BD2A-7DA3-4FC1-B3B1-0ADBCC43A294</gtr:id><gtr:title>The m.5650G&amp;gt;A mitochondrial tRNAAla mutation is pathogenic and causes a phenotype of pure myopathy.</gtr:title><gtr:parentPublicationTitle>Neuromuscular disorders : NMD</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/aceeebe176b2a13722db7069cd6fe796"><gtr:id>aceeebe176b2a13722db7069cd6fe796</gtr:id><gtr:otherNames>McFarland R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0960-8966</gtr:issn><gtr:outcomeId>2224287E98F</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5FCEAF97-C6E0-42D8-86AF-5EA1CF717492</gtr:id><gtr:title>The clinical presentation of mitochondrial diseases in children with progressive intellectual and neurological deterioration: a national, prospective, population-based study.</gtr:title><gtr:parentPublicationTitle>Developmental medicine and child neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2e326331ecce70beeda4b3a92a25dcd7"><gtr:id>2e326331ecce70beeda4b3a92a25dcd7</gtr:id><gtr:otherNames>Verity CM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0012-1622</gtr:issn><gtr:outcomeId>DCsKWesWqU8</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2D1B5F50-F419-4AFD-BDAC-87940D1E6047</gtr:id><gtr:title>Assigning pathogenicity to mitochondrial tRNA mutations: when &amp;quot;definitely maybe&amp;quot; is not good enough.</gtr:title><gtr:parentPublicationTitle>Trends in genetics : TIG</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/aceeebe176b2a13722db7069cd6fe796"><gtr:id>aceeebe176b2a13722db7069cd6fe796</gtr:id><gtr:otherNames>McFarland R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2004-01-01</gtr:date><gtr:issn>0168-9525</gtr:issn><gtr:outcomeId>pm_15296_16_15522452</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6ACAA0B3-1C54-43A5-8059-F10067F598B8</gtr:id><gtr:title>Mutation of OPA1 causes dominant optic atrophy with external ophthalmoplegia, ataxia, deafness and multiple mitochondrial DNA deletions: a novel disorder of mtDNA maintenance.</gtr:title><gtr:parentPublicationTitle>Brain : a journal of neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/65eb931f142b9d0a96c1e2e4b5b1f6a7"><gtr:id>65eb931f142b9d0a96c1e2e4b5b1f6a7</gtr:id><gtr:otherNames>Hudson G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0006-8950</gtr:issn><gtr:outcomeId>0CAFB0A75A9</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>88964B83-BE8D-4F1B-BF72-6A66353190F6</gtr:id><gtr:title>Phenotypic spectrum associated with mutations of the mitochondrial polymerase gamma gene.</gtr:title><gtr:parentPublicationTitle>Brain : a journal of neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/19fd4504ba711d599de3fabaf0f5338a"><gtr:id>19fd4504ba711d599de3fabaf0f5338a</gtr:id><gtr:otherNames>Horvath R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0006-8950</gtr:issn><gtr:outcomeId>365E62C71ED</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A12F12FF-F529-4285-A0E0-653F00452332</gtr:id><gtr:title>Pathogenic mitochondrial tRNA point mutations: nine novel mutations affirm their importance as a cause of mitochondrial disease.</gtr:title><gtr:parentPublicationTitle>Human mutation</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a4ee6ba0f820764b5675e3c255fdb95a"><gtr:id>a4ee6ba0f820764b5675e3c255fdb95a</gtr:id><gtr:otherNames>Blakely EL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1059-7794</gtr:issn><gtr:outcomeId>pm_15296_26_23696415</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>21754F5E-A8B6-445F-AF9D-C4B7DB1BE368</gtr:id><gtr:title>Pre-eclampsia and magnesium toxicity with therapeutic plasma level in a woman with m.3243A&amp;gt;G melas mutation.</gtr:title><gtr:parentPublicationTitle>Journal of obstetrics and gynaecology : the journal of the Institute of Obstetrics and Gynaecology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c0203de7eef17e89423cc198e7627924"><gtr:id>c0203de7eef17e89423cc198e7627924</gtr:id><gtr:otherNames>Moriarty KT</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0144-3615</gtr:issn><gtr:outcomeId>A025CFA4854</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>89EFEB12-9C8C-4039-BCA1-D8610A554E4E</gtr:id><gtr:title>Sporadic myopathy and exercise intolerance associated with the mitochondrial 8328G&amp;gt;A tRNALys mutation.</gtr:title><gtr:parentPublicationTitle>Journal of neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a4ee6ba0f820764b5675e3c255fdb95a"><gtr:id>a4ee6ba0f820764b5675e3c255fdb95a</gtr:id><gtr:otherNames>Blakely EL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0340-5354</gtr:issn><gtr:outcomeId>EADF8578406</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>11726BCF-5AC9-4EFD-AA4B-7D38C8371E9B</gtr:id><gtr:title>Catastrophic presentation of mitochondrial disease due to a mutation in the tRNA(His) gene.</gtr:title><gtr:parentPublicationTitle>Neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a3bc1e6261a073e8c97bb04481b8202a"><gtr:id>a3bc1e6261a073e8c97bb04481b8202a</gtr:id><gtr:otherNames>Taylor RW</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2004-01-01</gtr:date><gtr:issn>0028-3878</gtr:issn><gtr:outcomeId>pm_15296_16_15111688</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>48C73D81-9D16-4247-8E83-ACFF9DA0DA86</gtr:id><gtr:title>Pathogenic mitochondrial tRNA mutations--which mutations are inherited and why?</gtr:title><gtr:parentPublicationTitle>Human mutation</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/19cd9eac194029b31fc778c6567229da"><gtr:id>19cd9eac194029b31fc778c6567229da</gtr:id><gtr:otherNames>Elson JL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1059-7794</gtr:issn><gtr:outcomeId>E1HagwnkE5C</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>986B4C78-6C0F-4ADD-93CA-DBC5E41D2C68</gtr:id><gtr:title>Prevalence and progression of diabetes in mitochondrial disease.</gtr:title><gtr:parentPublicationTitle>Diabetologia</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0e87940e6460d8a108148a5e207bd528"><gtr:id>0e87940e6460d8a108148a5e207bd528</gtr:id><gtr:otherNames>Whittaker RG</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0012-186X</gtr:issn><gtr:outcomeId>88DB085A636</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BB3B7AC5-5530-40C4-B155-7AFDC04644E3</gtr:id><gtr:title>A comparative analysis approach to determining the pathogenicity of mitochondrial tRNA mutations.</gtr:title><gtr:parentPublicationTitle>Human mutation</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d934800bba4c6d737acf332a3f88b99e"><gtr:id>d934800bba4c6d737acf332a3f88b99e</gtr:id><gtr:otherNames>Yarham JW</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1059-7794</gtr:issn><gtr:outcomeId>pm_15296_26_21882289</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>17F17D72-8F43-4574-969A-A027B7876AC6</gtr:id><gtr:title>Familial myopathy: new insights into the T14709C mitochondrial tRNA mutation.</gtr:title><gtr:parentPublicationTitle>Annals of neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/aceeebe176b2a13722db7069cd6fe796"><gtr:id>aceeebe176b2a13722db7069cd6fe796</gtr:id><gtr:otherNames>McFarland R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2004-01-01</gtr:date><gtr:issn>0364-5134</gtr:issn><gtr:outcomeId>pm_15296_16_15048886</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7E69C083-46C1-43E2-A31B-009EC1E8C574</gtr:id><gtr:title>Mitochondrial tRNA mutations and disease.</gtr:title><gtr:parentPublicationTitle>Wiley interdisciplinary reviews. RNA</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d934800bba4c6d737acf332a3f88b99e"><gtr:id>d934800bba4c6d737acf332a3f88b99e</gtr:id><gtr:otherNames>Yarham JW</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1757-7004</gtr:issn><gtr:outcomeId>pm_15296_26_21935892</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>18536C49-90D5-4B53-9B77-104EAEDF117A</gtr:id><gtr:title>Proving pathogenicity: when evolution is not enough.</gtr:title><gtr:parentPublicationTitle>American journal of medical genetics. Part A</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/aceeebe176b2a13722db7069cd6fe796"><gtr:id>aceeebe176b2a13722db7069cd6fe796</gtr:id><gtr:otherNames>McFarland R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2004-01-01</gtr:date><gtr:issn>1552-4825</gtr:issn><gtr:outcomeId>pm_15296_16_15384096</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D5AB6998-C814-49D8-9257-45BE282A1665</gtr:id><gtr:title>A neurological perspective on mitochondrial disease.</gtr:title><gtr:parentPublicationTitle>The Lancet. Neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/aceeebe176b2a13722db7069cd6fe796"><gtr:id>aceeebe176b2a13722db7069cd6fe796</gtr:id><gtr:otherNames>McFarland R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1474-4422</gtr:issn><gtr:outcomeId>khMGM5yb8or</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>12FDF0E6-32D2-4D71-9537-E6D10AAEE6AB</gtr:id><gtr:title>Reversible valproate hepatotoxicity due to mutations in mitochondrial DNA polymerase gamma (POLG1).</gtr:title><gtr:parentPublicationTitle>Archives of disease in childhood</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/aceeebe176b2a13722db7069cd6fe796"><gtr:id>aceeebe176b2a13722db7069cd6fe796</gtr:id><gtr:otherNames>McFarland R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0003-9888</gtr:issn><gtr:outcomeId>76F83390477</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>36081E75-D128-4FAD-ACC4-207C32C1D921</gtr:id><gtr:title>A proposed consensus panel of organisms for determining evolutionary conservation of mt-tRNA point mutations.</gtr:title><gtr:parentPublicationTitle>Mitochondrion</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d934800bba4c6d737acf332a3f88b99e"><gtr:id>d934800bba4c6d737acf332a3f88b99e</gtr:id><gtr:otherNames>Yarham JW</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1567-7249</gtr:issn><gtr:outcomeId>pm_15296_26_22781547</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BF48A531-99EA-4FB7-BB70-3575C64D93A9</gtr:id><gtr:title>Mitochondrial disease in adults: a scale to monitor progression and treatment.</gtr:title><gtr:parentPublicationTitle>Neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/31c1147d31fcaeb7a6be3151b14a7bc9"><gtr:id>31c1147d31fcaeb7a6be3151b14a7bc9</gtr:id><gtr:otherNames>Schaefer AM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0028-3878</gtr:issn><gtr:outcomeId>3DB5C474E8C</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>ABCF18B9-46E9-4935-B73F-BD38FA165625</gtr:id><gtr:title>Prevalence of mitochondrial DNA disease in adults.</gtr:title><gtr:parentPublicationTitle>Annals of neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/31c1147d31fcaeb7a6be3151b14a7bc9"><gtr:id>31c1147d31fcaeb7a6be3151b14a7bc9</gtr:id><gtr:otherNames>Schaefer AM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0364-5134</gtr:issn><gtr:outcomeId>4E7F13769DE</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F12ECCB9-87D5-49BD-8C35-B363B6D496FF</gtr:id><gtr:title>The p.M292T NDUFS2 mutation causes complex I-deficient Leigh syndrome in multiple families.</gtr:title><gtr:parentPublicationTitle>Brain : a journal of neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/fe9015226fe85aa441230a01ec3c9484"><gtr:id>fe9015226fe85aa441230a01ec3c9484</gtr:id><gtr:otherNames>Tuppen HA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0006-8950</gtr:issn><gtr:outcomeId>BNJE72isS8e</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4525D56F-250B-41E9-84C7-57F3209D91E7</gtr:id><gtr:title>Childhood neurological presentation of a novel mitochondrial tRNA(Val) gene mutation.</gtr:title><gtr:parentPublicationTitle>Journal of the neurological sciences</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a4ee6ba0f820764b5675e3c255fdb95a"><gtr:id>a4ee6ba0f820764b5675e3c255fdb95a</gtr:id><gtr:otherNames>Blakely EL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2004-01-01</gtr:date><gtr:issn>0022-510X</gtr:issn><gtr:outcomeId>pm_15296_16_15465092</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3CC26F4B-FD58-436B-B6FC-12D7916270CA</gtr:id><gtr:title>Molecular basis of infantile reversible cytochrome c oxidase deficiency myopathy.</gtr:title><gtr:parentPublicationTitle>Brain : a journal of neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/19fd4504ba711d599de3fabaf0f5338a"><gtr:id>19fd4504ba711d599de3fabaf0f5338a</gtr:id><gtr:otherNames>Horvath R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0006-8950</gtr:issn><gtr:outcomeId>MXMaTce38ue</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BD5988BD-44AB-4F20-AD90-612BDB90E15C</gtr:id><gtr:title>Overexpression of human mitochondrial valyl tRNA synthetase can partially restore levels of cognate mt-tRNAVal carrying the pathogenic C25U mutation.</gtr:title><gtr:parentPublicationTitle>Nucleic acids research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/32c739ac12bf8fb6b582f9ac7f6af3f3"><gtr:id>32c739ac12bf8fb6b582f9ac7f6af3f3</gtr:id><gtr:otherNames>Rorbach J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0305-1048</gtr:issn><gtr:outcomeId>3C39234DE3C</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G108/539</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>F3822669-BB5A-4BB4-BAE0-DCB9DE36E092</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Generic Health Relevance</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>